SCHEMBL3343202

SCHEMBL3343202

OC1CNCC(O)CNC1

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAN1B1 Q9UKM7 1/20 0.57
GBA1 P04062 6/20 0.50
FUCA1 P04066 4/20 0.50
GLA P06280 2/20 0.50
GAA P10253 2/20 0.50
GLB1 P16278 2/20 0.50
CCR5 P51681 1/20 0.43
NOS2 P35228 1/20 0.35
PYGL P06737 1/20 0.35
GBA2 Q9HCG7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48555 0.95
Hydrochloric Acid SCHEMBL27450396 0.91
Hydrochloric Acid SCHEMBL24204 0.91
Bromide SCHEMBL27700910 0.91
Methane SCHEMBL28046548 0.91
Methane SCHEMBL28870704 0.87
Hydrochloric Acid SCHEMBL221781 0.87
Ethane SCHEMBL9684365 0.87
SCHEMBL1992553 0.84
SCHEMBL16906285 0.84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160626-A1 Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes ASTRAZENECA AB (SE) 2010-06-24 US disclosed
US-20100160626-A1 Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes ASTRAZENECA AB (SE) 2010-06-24 US disclosed
US-20090240051-A1 New process for the production of oxabispidines ASTRAZENECA AB (SE) 2009-09-24 US disclosed
US-20090036675-A1 New process for production of oxabispidines ASTRAZENECA AB (SE) 2009-02-05 US disclosed
US-7439355-B2 Process for the production of oxabispidines ASTRAZENECA AB (SE) 2008-10-21 US disclosed
CN-101203520-A Process for the preparation of 3,7-dihydroxy-1,5-diazacyclooctanes ASTRAZENECA AB (SE) 2008-06-18 CN disclosed
EP-1900741-A1 New process for the production of oxabispidines AstraZeneca AB (SE) 2008-03-19 EP disclosed
EP-1896486-A1 PROCESS FOR THE PREPARATION OF 3,7-DIHYDROXY-1,5-DIAZACYCLOOCTANES AstraZeneca AB (SE) 2008-03-12 EP disclosed
US-20070197519-A1 New Process For The Preparation Of Oxabispidines ASTRAZENECA AB (SE) 2007-08-23 US disclosed
US-7169921-B2 Process for the preparation of oxabispidines ASTRAZENECA AB (SE) 2007-01-30 US disclosed
US-20050171100-A1 Process for the production of oxabispidines ASTRAZENECA AB (SE) 2005-08-04 US disclosed
EP-1385850-B1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES ASTRAZENECA AB (SE) 2004-12-08 EP disclosed
US-20040181060-A1 Process for the preparation of oxabispidines ASTRAZENECA AB (SE) 2004-09-16 US disclosed
US-20040133000-A1 Process for the preparation of oxabispidines ASTRAZENECA AB (SE) 2004-07-08 US disclosed
EP-1385851-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES AstraZeneca AB (SE) 2004-02-04 EP disclosed
EP-1385850-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES AstraZeneca AB (SE) 2004-02-04 EP disclosed
EP-1330462-A1 NEW PROCESS FOR THE PRODUCTION OF OXABISPIDINES AstraZeneca AB (SE) 2003-07-30 EP disclosed
WO-2002083691-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES ASTRAZENECA AB (SE) 2002-10-24 WO disclosed
WO-2002083690-A1 NEW PROCESS FOR THE PREPARATION OF OXABISPIDINES ASTRAZENECA AB (SE) 2002-10-24 WO disclosed
WO-2002028864-A1 NEW PROCESS FOR THE PRODUCTION OF OXABISPIDINES ASTRAZENECA AB (SE) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050171100-A1 Process for the production of oxabispidines AVPR1B, CCNB3, CCNB1 MAN1B1 252/4885GBA1 665/4885FUCA1 2813/4885
US-20090240051-A1 New process for the production of oxabispidines AVPR1B, CCNB1, QDPR MAN1B1 160/4885GBA1 850/4885FUCA1 2961/4885
US-20090036675-A1 New process for production of oxabispidines AVPR1B, CCNB1, DHPS MAN1B1 143/4885GBA1 943/4885FUCA1 3096/4885
US-20040133000-A1 Process for the preparation of oxabispidines CYP1B1, ATP1B1, MAOB MAN1B1 29/4885GBA1 316/4885FUCA1 1307/4885
US-20070197519-A1 New Process For The Preparation Of Oxabispidines TST, IDH3B, INTS6 MAN1B1 1985/4885GBA1 4123/4885FUCA1 4293/4885
US-20040181060-A1 Process for the preparation of oxabispidines ADH1C, ADH1A, CYP2E1 MAN1B1 398/4885GBA1 3755/4885FUCA1 3362/4885
US-20100160626-A1 Process For The Preparation Of 3,7-Dihydroxy-1,5-Diazacyclooctanes CYP2D6, KCNH1, CYP2B6 MAN1B1 859/4885GBA1 1934/4885FUCA1 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.